Institutional shares held 79.5 Million
23.3K calls
44.3K puts
Total value of holdings $4.29B
$1.26M calls
$2.39M puts
Market Cap $2.9B
53,752,800 Shares Out.
Institutional ownership 147.99%
# of Institutions 241


Latest Institutional Activity in CRNX

Top Purchases

Q3 2024
Vanguard Group Inc Shares Held: 6.29M ($339M)
Q3 2024
Siren, L.L.C. Shares Held: 1.31M ($70.7M)
Q3 2024
Farallon Capital Management LLC Shares Held: 1.16M ($62.7M)
Q3 2024
Pictet Asset Management Holding Sa Shares Held: 908K ($49M)
Q3 2024
Price T Rowe Associates Inc Shares Held: 4.94M ($267M)

Top Sells

Q3 2024
Perceptive Advisors LLC Shares Held: 725K ($39.1M)
Q3 2024
Point72 Asset Management, L.P. Shares Held: 2.3M ($124M)
Q3 2024
Saturn V Capital Management LLC Shares Held: 110K ($5.91M)
Q3 2024
Stem Point Capital LP Shares Held: 214K ($11.5M)
Q3 2024
T. Rowe Price Investment Management, Inc. Shares Held: 1.07M ($57.7M)

About CRNX

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.


Insider Transactions at CRNX

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
787K Shares
From 22 Insiders
Grant, award, or other acquisition 200K shares
Exercise of conversion of derivative security 527K shares
Bona fide gift 60K shares
Sell / Disposition
648K Shares
From 15 Insiders
Payment of exercise price or tax liability 26.8K shares
Open market or private sale 561K shares
Bona fide gift 60.4K shares

Track Institutional and Insider Activities on CRNX

Follow Crinetics Pharmaceuticals, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CRNX shares.

Notify only if

Insider Trading

Get notified when an Crinetics Pharmaceuticals, Inc. insider buys or sells CRNX shares.

Notify only if

News

Receive news related to Crinetics Pharmaceuticals, Inc.

Track Activities on CRNX